The purpose of the study is to find out how a small dose of insulin might affect memory, the
ability to concentrate, and improve your daily functioning in patients with schizophrenia
and schizoaffective disorders. Insulin is not being used to treat diabetes in this study.
The investigators propose a single dose, double-blinded, placebo-controlled trial of
intranasal insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine
insulin's effect on cognition. The specific aims include:
1. Examine the effects of single doses of 40 IU intranasal insulin compared to placebo on
cognitive functioning, including attention and memory.
2. Examine whether single dose of intranasal insulin administration will raise serum
insulin level and decrease plasma glucose level
Insulin will be delivered through an air spray pump into your nose. The investigators will
be comparing one dose of insulin (40 International Units) with placebo, an inactive liquid.
Insulin signaling in the brain is associated with improved cognitive function in both animal
and human studies. Intranasal administration of insulin, which is non-invasive and
minimizes the risk of hypoglycemia, may represent a new intervention approach with the
potential to improve cognition and real life functioning in this patient with schizophrenia.
- Age 18-65 years
- Diagnosis of schizophrenia, any subtype or schizoaffective disorder, any subtype
- Male or female
- Stable dose of the current antipsychotic drug for at least one month
- Well established compliance with out-patient treatment per treating clinician's
- Able to complete the cognitive assessment battery (must be English speaking)
- Inability to provide informed consent
- Current substance abuse
- On clozapine or olanzapine
- Psychiatrically unstable per treating clinician's judgement.
- Significant medical illnesses including uncontrolled hypertension, diabetes, seizure
disorder, severe cardiovascular, cerebrovascular, pulmonary, or thyroid diseases etc.
- Incapable to complete the cognitive battery assessment.
Xiaoduo Fan, MD, MPH, MS
UMass Medical School